Audentes Therapeutics, Inc., a San Francisco, CA-based biotechnology company committed to the development and commercialization of gene therapy products for patients with serious, rare diseases, closed a $65m Series C financing.
The round was co-led by existing investor Sofinnova Ventures and new investor Redmile Group with participation from new investors RA Capital Management, funds and accounts advised by T. Rowe Price Associates, Inc., Rock Springs Capital Management LP, Cormorant Asset Management LLC, Cowen Private Investments, and Foresite Capital, as well as existing investors OrbiMed, 5AM Ventures, Versant Ventures, Deerfield Management Company and Venrock.
The company intends to use the funds to advance three lead development programs to key clinical milestones and to establish internal GMP manufacturing capabilities.
Led by Matthew Patterson, President and Chief Executive Officer, Audentes Therapeutics is committed to the development and commercialization of innovative new treatments for people with serious, rare diseases through the application of AAV gene therapy technology.
It has three products in development, AT001 for the treatment of X-Linked Myotubular Myopathy (XLMTM), AT002 for the treatment of Pompe disease, and AT003 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).